Pharma Pulse 4/8/25: Banks Postpone Loans as Tariffs Stoke Fears, GLP-1 and Biosimilars Trends & more
The latest news for pharma industry insiders.
Addressing Underrepresentation of Racial & Ethnic Groups in Psoriasis Trials
In this Pharmaceutical Executive video interview, LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses strategies to address underrepresentation in clinical trials, particularly in phase III psoriasis trials. Robinson also discusses the company's partnerships with community stakeholders like Inside Edge, Black Health Matters, and Hispanic Communication Global Network to improve engagement, address operational barriers, and prioritize sites with diverse patient demographics. Takeda also enhanced investigator diversity through multilingual toolkits and educational sessions, and aims to expand these efforts globally by adapting strategies to regional needs.
GLP-1 and Biosimilars Trends, Impact on Payers and Costs | AMCP Annual 2025
Doug Long, BA, MBA, vice president of Industry Relations at IQVIA, shares what's happening in the growing GLP-1 and biosimilars space. Long was a presenter at the annual AMCP 2025 meeting in Houston, where he discussed these topics and more earlier this week.
Banks Postpone Loans as Tariffs Stoke Fears of ‘Hung’ Debt
Wall Street lenders are postponing leveraged-finance deals as investors shy away from risky transactions while global markets convulse in the wake of US President Donald Trump’s sweeping tariffs.
Hello Heart Unveils Connected Pill Box to Radically Improve Medication Adherence
Hello Heart has introduced Hello Heart Pill Box, a proprietary smart pill box designed to improve medication adherence. This addition to Hello Heart’s suite of heart health tools, including its blood pressure monitor and mobile app, addresses one of the most critical factors of cardiovascular care management.
As the popularity and use of GLP-1s increases, the price has remained the same 💰
Even with insurance, patients sometimes pay $500-$600 out of pocket for weight-loss injectables—and research has shown that even a $100 copay can have a negative effect on first-fill rates, says Colin Banas, M.D., M.H.A.,DrFirst, Inc. Chief Medical Officer.
Hear more in this interview with Pharmaceutical Commerce👇
https://bit.ly/3DWZLD4
Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs
